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ABSTRACT
Introduction/Objectives: Evaluate clinical practice through assessment of vaccination card and recommendation of 
specific vaccines in pediatric patients with rheumatic diseases in use of different drugs and reveal the possible association 
between vaccination frequency and time of the clinical practice of pediatric rheumatologists in the state of São Paulo. 
Material and Methods: A questionnaire was sent to pediatric rheumatologists of the Departamento de Reumatologia da 
Sociedade de Pediatria de São Paulo. This instrument included questions about practice time on Pediatric Rheumatology, 
vaccination of patients with juvenile systemic lupus erythematosus (JSLE), juvenile idiopathic arthritis (JIA), juvenile 
dermatomyositis (JDM), and immunization according to the treatments used. Results: Vaccination card was seen by 
100% of the professionals at the first visit and by 36% annually. Vaccines of live agents were not recommended for 
patients with JSLE, JIA, and JDM in 44%, 64%, and 48%, respectively. The professionals were divided into two groups: 
Group A (≤ 15 years of practice, n = 12) and B (≥ 16 years, n = 13). No statistical difference was observed in the use of 
live agent vaccine and vaccines with inactivated agents or protein components in the two treatment groups (P > 0.05). 
Moreover, the groups had similar opinion regarding severity of immunosuppression in patients with JSLE, JIA, and 
JDM (with or without activity) and treatment used (P > 0.05). Conclusions: The frequency of immunization by pediatric 
rheumatologists in São Paulo is low, especially after the first visit, and not influenced by time of professional practice.
Keywords: vaccination, children, systemic lupus erythematosus, juvenile idiopathic arthritis, rheumatic disease. 
INTRODUCTION
Infections are a major cause of morbidity and mortality in 
Brazilian children and teenagers with chronic rheumatic 
diseases. In some children, particularly those with systemic 
lupus erythematosus (JSLE),1,2 juvenile idiopathic arthritis 
(JIA), and juvenile dermatomyositis (JDM),3 not only the 
treatment used but the disease itself establishes a state of 
immunosuppression.
 One of the preventive measures against infectious 
disease is passive immunization.4-6 The primary vaccination 
schedule is applied especially during childhood and 
adolescence, the age group with the highest prevalence of 
certain rheumatic diseases. Although inactivated vaccines 
agents have proved generally safe in patients with rheumatic 
diseases, some studies in adults have shown activation 
of disease after vaccination.7 Furthermore, vaccines may 
not induce adequate immunogenicity in patients using 
potentially immunosuppressive drugs. Recently, our concern 
with these issues was highlighted in a systematic review 
of medical literature on efficacy and safety of vaccines in 
children and adolescents with rheumatic diseases based on 
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levels of scientific evidence.8 This consensus demonstrated 
the safety and efficacy of inactivated vaccines and protein 
components against virus, such as hepatitis A and B, influenza, 
pneumococcus, meningococcus, Haemophilus, Salk, and 
tetanus, in patients with rheumatic diseases, despite the 
use of immunosuppressive drugs. Furthermore, this review 
suggested that vaccination with live agents against yellow 
fever, BCG, rotavirus, varicella, polio, and MMR are 
contraindicated in immunosuppressed patients.
 However, few studies have assessed the clinical practice 
of pediatric rheumatologists in immunization of these diseases. 
Davies & Woo forwarded a questionnaire to members of 
the English Group of Pediatric Rheumatology and observed 
inconsistency in immunization practice among specialists from 
different British services.9
 The time of clinical practice allows more opportunity 
to comment on vaccination considering protection and risk 
in a larger number of patients with rheumatic diseases. 
Furthermore, over time, there was refinement in vaccination 
practice with better knowledge and greater availability of 
vaccines, especially with the emergence of Reference Centers 
of Special Immunobiologic Products.
 Study evaluating the immunization practice according 
to the years of practice has not been done. The objective of 
this study was to evaluate the clinical practice of vaccinations 
recommended by pediatric rheumatologists in the state of São 
Paulo for children and adolescents with rheumatic diseases, 
similar to the British study, and to reveal a possible association 
between increased frequency of immunization prescription by 
professionals and longer practice in the specialty.
MATERIAL AND METHODS
During April of 2009, a questionnaire on immunization 
practices was sent by e-mail to 26 pediatric rheumatologists 
of Departamento de Reumatologia Pediátrica da Sociedade 
de Pediatria de São Paulo (SPSP). This questionnaire was 
sent three times consecutively within two weeks. Of the 26 
professionals, 25 (96%) answered the questionnaire. All 
medical specialists have qualification certificate in Pediatric 
Rheumatology and/or Rheumatology and act in daily teaching 
activities, care, and research.
 The questionnaire included open questions and issues 
related to immunization practice. Some of these questions 
were modified from Davies & Woo9 (questions 5 and 6). The 
following open questions were included:
• How long (in years) have you been 
practicing pediatric rheumatology?
• Which vaccines are routinely recommended (when 
there is no contraindication) to patients with JSLE 
(American College of Rheumatology classification 
criteria),10 JIA (International League of Associations 
for Rheumatology classification criteria),11 and 
JDM (Bohan & Peter classification criteria)? 12
• The vaccination card is seen at the first visit?
• How many times vaccination card is seen in follow-up?
• Personal opinion regarding the indication and 
contraindication of specific vaccines in patients 
with rheumatic diseases of childhood using 
different doses and combination drugs.
The frequency of recommendations of the following 
vaccines were assessed: inactivated vaccines and protein 
components [against hepatitis A and B, human papilloma virus 
(HPV), influenza, pneumococcal, meningococcal, tetanus and 
diphtheria toxoids, inactivated polio and Haemophilus] and live 
attenuated agent vaccines [against polio, measles, mumps and 
rubella (MMR), bacillus Calmette-Guerin (BCG), rotavirus, 
yellow fever, and chickenpox].
Treatments with prednisone at different doses (above or below 
2 mg/kg/day) were evaluated and the use of the following drugs 
independent of doses: immunosuppressive (IS) and/or disease-
modifying drugs (DMDs) [Methotrexate (MTX), antimalarials 
(chloroquine and hydroxychloroquine), sulfasalazine, leflunomide, 
azathioprine, cyclosporine, mycophenolate mofetil and 
cyclophosphamide] and biological agents.
• Personal opinion on the intensity of immunosuppression 
resulting from the use of corticosteroids (CT) at 
different doses, IS drugs and/or DMARDs [MTX 
in increasing doses, antimalarial drugs (chloroquine 
and hydroxychloroquine), sulfasalazine, leflunomide, 
azathioprine, cyclosporine, mycophenolate 
mofetil and cyclophosphamide] and biological 
agents in JIA, JDM, and JSLE diseases.
Later, participants were divided into two groups according 
to the median time (years) of pediatric rheumatology practice 
(from the first year of residency or internship in the specialty to 
April 30, 2009): group A (≤ 15 years of pediatric rheumatology 
practice) and group B (≥ 16 years of practice).
Statistical analysis
The time of clinical practice in pediatric rheumatology was 
presented as median (range), compared between groups A and 
B by Mann-Whitney test. Categorical variables were presented 
as number (%) and compared using Fisher exact test. The 
significance level of 5% (P < 0.05) was used for all statistical tests.
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RESULTS
Table 1 shows the frequency of different vaccines 
recommendation for patients with JSLE, JIA, and JDM by 
the 25 professionals interviewed. Inactivated vaccines were 
recommended for all three diseases by over 50% of pediatric 
rheumatologists. There was an emphasis on vaccines not 
included in the basic schedule of immunizations, especially 
influenza vaccine (indicated by 76% of professionals) and 
pneumococcal (indicated by 84% of professionals to JSLE 
patients, 68% to JIA, and 72% to JDM).
 The vaccination card was checked at the first visit by 
100% of specialists and annually by just nine of 25 (36%). 
There was no statistical difference between the median time of 
pediatric rheumatology practice in the group that checked the 
immunization card every year and the group that did not have 
this behavior [15 (9-27) versus 19 (30-40) years, P = 0.91].
 The frequency of vaccine indications by pediatric 
rheumatologists according to disease and treatment is shown 
in Table 2. Eighteen (72%) physicians reported the use of 
live agent vaccines, generally in patients with non-steroidal 
anti-inflammatory drugs (NSAIDs) or not using CT, MTX, or 
other immunosuppressive drugs. Furthermore, 24 (96%) of 
professionals reported using inactivated vaccines in pediatric 
patients with rheumatic diseases in the same situations 
described above.
 We evaluated the opinions of 25 professionals in 
accordance with the risk of infection or disease treatment. 
Regarding the risk of infection, JSLE in activity was considered 
as the rheumatic diseases of childhood that provides moderate 
to high risk of infection by most professionals (96%). Similarly, 
JDM and systemic JIA in activity were also considered to 
carry a high risk of infections (80% and 68%, respectively). 
The percentage of participants who considered moderate to 
severe risk of infection was proportional to the increased dose 
of corticosteroids (8% at doses below 0.2 mg/kg/day to 100% 
at doses above 2 mg/kg/day), which also occurred with the 
use of MTX. The IS (azathioprine, cyclophosphamide, and 
mycophenolate mofetil) and biological agents were considered 
drugs with high risk of serious infections.
 The difference in practice time did not result in discrepancies 
in live or inactivated agent vaccine recommendations in 
general, according to treatment used (NSAIDs, CT, MTX, IS, 
and biological agents) by the two groups (P> 0.05; Table 3). 
Likewise, there was no statistical difference between the two 
groups regarding the level of immunosuppression assigned 
to rheumatic diseases of childhood with or without clinical 
activity (JSLE, JIA, and JDM) and treatment used (NSAIDs, 
CT, MTX, IS, and biological agents ) (P > 0.05).
DISCUSSION
The present study demonstrates that the clinical practice 
regarding immunization is homogeneous among pediatric 
rheumatologists, despite the heterogeneity of practice time in 
the field. However, only about a third of the specialists have 
adequate surveillance of vaccine card after the first medical visit.
 The two groups had very similar views regarding vaccine 
guidance and definition of serious risk of infections. Moreover, 
there was agreement on some of the responses in more than 80% 
of medical specialists. By definition, this high frequency between 
the two groups is considered a “consensus among experts”.13 In 
this research, there are doctors of various age groups that were 
formed in the same department of Pediatric Rheumatology by 
colleagues of various generations. This fact probably justifies the 
similarity of the medical practices. In addition, all participants 
work in university services, participate in continuing medical 
education, and most have post-graduate studies.
 An important aspect, however, was the low standard 
indication by experts of vaccines against hepatitis A and B, 
Table 1
Vaccines routinely recommended by 25 pediatric 
rheumatologists according to disease
Vaccines
JSLE 
N (%)
JIA
N (%)
JMD
N (%)
dT or dTap* 18 (72) 18 (72) 18 (72)
SALK* 13 (52) 13 (52) 13 (52)
Haemophilus* 14 (56) 15 (60) 14 (56)
Influenza* 19 (76) 19 (76) 19 (76)
Pneumococcal* 21 (84) 17 (68) 18 (72)
Meningitis C* 16 (64) 15 (60) 15 (60)
Hepatitis A* 14 (56) 13 (52) 14 (56)
Hepatitis B* 14 (56) 14 (56) 18 (72)
MMR without CT and IS 3 (12) 8 (32) 3 (12)
MMR with CT 
< 2 mg/kg/day, without IS 5 (20) 5 (20) 4 (16)
Varicella without CT and IS 2 (8) 3 (12) 3 (12)
Varicella with CT 
< 2 mg/kg/day, without IS 2 (8) 3 (12) 3 (12)
Yellow fever without CT and IS 2 (8) 3 (12) 2 (8)
Yellow fever with CT 
< 2 mg/kg/day, without IS 2 (8) 1 (4) 2 (8)
JSLE = juvenile systemic lupus erythematosus; JIA = juvenile idiopathic arthritis;  
JDM = juvenile dermatomyositis; DPT = diphtheria, pertussis and tetanus;  
DTaP = acellular triple bacterial; CT = corticosteroids; IS = immunosuppressants.
* Vaccines given regardless of treatment used and disease activity.
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Salk, Haemophilus and meningococcal C. All of them are 
composed of inactivated agents and therefore considered safe. 
These low rates of vaccination included patients at high risk of 
infection according to the same professionals. Possibly, this fact 
is explained by the remaining concern about the exacerbation or 
reactivation of disease, as recorded in JSLE patients following 
immunization against hepatitis B.7
 Recently, pediatric rheumatologist members of the 
Department of Pediatric Rheumatology of SPSP met to 
establish consensus about immunization for patients with 
rheumatic diseases with onset in childhood and adolescence. 
At this point, a questionnaire was sent to all these renowned 
experts, which enabled this research. According to this 
consensus, it was concluded that there are few studies on 
efficacy and safety of using vaccines for these diseases in 
pediatric patients.8
 According to the American Academy of Pediatrics, 
immunization with live vaccine component is contraindicated 
when prednisone is used in doses equal to or greater than 
2 mg/kg or higher than 20 mg/day, for longer than a week.14 
The Committee of Immunization Practices of the CDC instructs 
that live agents vaccines can be used in patients on MTX 
at doses ≤ 0.4 mg/kg/week or 28 mg/week in an individual 
with 70 kg, azathioprine ≤ 3 mg/kg/day, or 6-mercaptopurine 
≤ 1.5 mg/kg/day. The combination of these drugs with other 
immunosuppressant is not indicative of immunization.15
 Davies & Woo found that, in the opinion of 24 
rheumatologists from the British pediatric rheumatology 
group, the dose of CT that contraindicated the use of live 
attenuated virus vaccine (such as varicella vaccine) for children 
with rheumatic diseases was extremely varied.9 This effect 
was also observed among physicians specialized in pediatric 
rheumatology in the state of São Paulo participating in this 
study.
 Over the years of follow-up and treatment with 
immunosuppressive drugs, surveillance of immunization 
with vaccination card was held by only 36% of the medical 
specialists. This study reinforces the need to include the 
item “vaccination” in the evolutionary medical record for all 
rheumatic diseases of childhood.
 According to physicians, high risk of infection is associated 
with patients with JSLE and JDM. Immunosuppression of 
lupus is multifactorial and includes immunological changes 
characteristic of disease (dysfunction of phagocytes, 
lymphopenia, functional asplenia, reduced cytokines, 
immunoglobulins, and complement fractions), use of 
Table 2
Vaccines indicated by 25 pediatric rheumatologists according to treatment used
With
NSAIDs 
N (%)
Without 
MTX, IS, or 
CTN (%)
MTX or 
single IS 
N (%)
Prednisone < 
2 mg/kg/day 
without MTX 
or IS N (%)
Prednisone < 
2 mg/kg/day, 
with MTX or 
IS N (%)
Prednisone > 
2 mg/kg/day 
without MTX 
or IS N (%)
Prednisone 
> 2 mg/kg/
day with MTX 
or IS N (%)
With 
biological 
agents 
(anti-TNf, 
rituximab or 
abatacept) 
N (%)
Live agent vaccines 
in general 18 (72) 18 (72) 1 (4) 2 (8) 2 (8) 0 (0) 0 (0) 0 (0)
Inactive vaccines 
in general 24 (96) 24 (96) 23 (92) 22 (88) 20 (80) 19 (76) 19 (76) 18 (72)
Oral polio vaccine 20 (80) 19 (76) 2 (8) 4 (16) 2 (8) 1 (4) 1 (4) 1 (4)
MMR vaccine 22 (88) 21 (84) 3 (12) 6 (24) 2 (8) 1 (4) 1 (4) 1 (4)
BCG vaccine 20 (80) 19 (76) 1 (4) 1 (4) 0 (0) 0 (0) 0 (0) 0 (0)
Yellow fever vaccine 21 (84) 21 (84) 0 (0) 3 (12) 0 (0) 0 (0) 0 (0) 0 (0)
Chickenpox vaccine 19 (76) 23 (92) 3 (12) 6 (24) 1 (4) 0 (0) 0 (0) 0 (0)
HPV vaccine 22 (88) 21 (84) 16 (64) 16 (64) 14 (56) 13 (52) 13 (52) 13 (52)
Meningococcal vaccine 25 (100) 24 (96) 22 (88) 21 (84) 19 (76) 18 (72) 18 (72) 18 (72)
Hepatitis B vaccine 24 (96) 23 (92) 22 (88) 21 (84) 20 (80) 19 (76) 19 (76) 19 (76)
Hepatitis A vaccine 24 (96) 23 (92) 22 (88) 21 (84) 20 (80) 19 (76) 19 (76) 19 (76)
Influenza virus vaccine 22 (88) 23 (92) 20 (80) 19 (76) 18 (72) 17 (68) 17 (68) 17 (68)
DTP or Td vaccine * 21/21 (100) 20/21 (95) 19/21 (90) 17/21 (81) 16/21 (76) 15/21 (71) 15/21 (71) 14/21 (67)
NSAIDs = non-steroidal anti-inflammatory drugs; MTX = methotrexate; IS = immunosuppressant (azathioprine, cyclophosphamide, cyclosporine or mycophenolate mofetil);  
TNF = tumor necrosis factor; BCG = bacillus Calmette-Guerin; MMR = measles, mumps and rubella; HPV = human papillomavirus; DPT = diphtheria, pertussis and tetanus.
* Four of 25 physicians interviewed reported that they vaccinated all patients up to 6 years of age with DPT, with rheumatic diseases 
and under any treatment, and patients older than 7 years with Td or DTaP (acellular triple bacterial).
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immunosuppressive, and disease activity.3,4 Infections also 
result in high mortality rates (between 9% and 30%) in 
patients with dermatomyositis.16 Lymphopenia, esophageal 
dysfunction, ventilatory insufficiency, interstitial lung disease, 
and calcinosis cutis are considered predictive parameters for 
infection in inflammatory myopathies.16
 Some drugs commonly used for treatment of rheumatic 
diseases, such as CT, MTX, azathioprine, cyclosporine A, 
cyclophosphamide, and tumor necrosis factor inhibitors 
(anti-TNF) are potentially immunosuppressive17,18 and were 
associated with high risk of infection by experts in this study. 
As expected, the use of NSAIDs and antimalarial drugs was 
considered low risk.
 Some live virus vaccines are noteworthy. For children 
and adolescents with rheumatic diseases, the ideal would be 
to indicate the vaccine to children susceptible before starting 
immunosuppressive drug.15
 Vaccines against varicella and yellow fever were 
contraindicated by all specialists in this study for patients 
receiving high-dose CT with or without the use of 
immunosuppressants. However, patients with rheumatic 
diseases present higher risk for severe varicella19 and herpes 
zoster,20 in addition to additional risks related to chronic use 
of anti-inflammatory21,22 and possible induction of macrophage 
activation syndrome by this virus.23
 Despite concerns about the use of live agent vaccines, recent 
studies demonstrate the safety of its use in immunosuppressed 
patients. In a study conducted in Brazil, 25 pediatric patients 
with rheumatic diseases were selected and vaccinated against 
chickenpox. All patients were receiving MTX and 11 patients 
also received CT. No patient developed varicella and/or 
serious adverse events following vaccination. Moreover, 
no worsening in the activity of rheumatic diseases has been 
verified.24 Another Brazilian study reported the practice of 
vaccination against yellow fever in seventy adult patients with 
rheumatic diseases, with mild adverse events observed in 22% 
of patients.25
 In conclusion, the practice of immunization surveillance 
by pediatric rheumatologists is low, especially after the first 
visit, possibly due to lack of efficacy and safety of vaccines 
in children and adolescents with rheumatic diseases. The 
frequency of indicating vaccines routinely is not influenced 
by the time of professional practice. Thus, the use of 
Consensus on Immunization for children and adolescents 
with rheumatic disease and regular checking of immunization 
cards, including teenagers, might improve the frequency 
vaccine recommendation in these patients. Furthermore, future 
multicentric trials including expressive populations of patients 
are needed.
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